BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases. 1982

C M Camaggi, and E Strocchi, and V Tamassia, and A Martoni, and M Giovannini, and G Lafelice, and N Canova, and D Marraro, and A Martini, and F Pannuti

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015251 Epirubicin An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. 4'-Epiadriamycin,4'-Epidoxorubicin,4'-Epi-Adriamycin,4'-Epi-DXR,4'-Epi-Doxorubicin,EPI-cell,Ellence,Epilem,Epirubicin Hydrochloride,Farmorubicin,Farmorubicina,Farmorubicine,IMI-28,NSC-256942,Pharmorubicin,4' Epi Adriamycin,4' Epi DXR,4' Epi Doxorubicin,4' Epiadriamycin,4' Epidoxorubicin,EPI cell,EPIcell,Hydrochloride, Epirubicin,IMI 28,IMI28,NSC 256942,NSC256942

Related Publications

C M Camaggi, and E Strocchi, and V Tamassia, and A Martoni, and M Giovannini, and G Lafelice, and N Canova, and D Marraro, and A Martini, and F Pannuti
Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients.
January 1989, Cancer chemotherapy and pharmacology,
C M Camaggi, and E Strocchi, and V Tamassia, and A Martoni, and M Giovannini, and G Lafelice, and N Canova, and D Marraro, and A Martini, and F Pannuti
Pharmacokinetic and therapeutic studies of pivmecillinam in patients with normal and impaired renal function.
January 1978, Scandinavian journal of infectious diseases,
C M Camaggi, and E Strocchi, and V Tamassia, and A Martoni, and M Giovannini, and G Lafelice, and N Canova, and D Marraro, and A Martini, and F Pannuti
Pharmacokinetic studies of cefuroxime and dosage recommendations in patients with impaired renal function.
January 1977, Proceedings of the Royal Society of Medicine,
C M Camaggi, and E Strocchi, and V Tamassia, and A Martoni, and M Giovannini, and G Lafelice, and N Canova, and D Marraro, and A Martini, and F Pannuti
Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function.
January 1983, Reviews of infectious diseases,
C M Camaggi, and E Strocchi, and V Tamassia, and A Martoni, and M Giovannini, and G Lafelice, and N Canova, and D Marraro, and A Martini, and F Pannuti
Phase II study of 4'-epi-doxorubicin in metastatic renal cancer.
May 1982, Cancer treatment reports,
C M Camaggi, and E Strocchi, and V Tamassia, and A Martoni, and M Giovannini, and G Lafelice, and N Canova, and D Marraro, and A Martini, and F Pannuti
A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function.
December 2016, Cancer chemotherapy and pharmacology,
C M Camaggi, and E Strocchi, and V Tamassia, and A Martoni, and M Giovannini, and G Lafelice, and N Canova, and D Marraro, and A Martini, and F Pannuti
Comparative enantioselective pharmacokinetic studies of celiprolol in healthy volunteers and patients with impaired renal function.
January 1990, European journal of clinical pharmacology,
C M Camaggi, and E Strocchi, and V Tamassia, and A Martoni, and M Giovannini, and G Lafelice, and N Canova, and D Marraro, and A Martini, and F Pannuti
Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.
November 2015, Cancer chemotherapy and pharmacology,
C M Camaggi, and E Strocchi, and V Tamassia, and A Martoni, and M Giovannini, and G Lafelice, and N Canova, and D Marraro, and A Martini, and F Pannuti
Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.
March 2004, Clinical therapeutics,
C M Camaggi, and E Strocchi, and V Tamassia, and A Martoni, and M Giovannini, and G Lafelice, and N Canova, and D Marraro, and A Martini, and F Pannuti
Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function.
January 1977, Journal of clinical pharmacology,
Copied contents to your clipboard!